Progesterone Suppository Uses in Early Pregnancy and IVF

Progesterone suppositories are small, solid doses of the hormone progesterone designed to be inserted vaginally (or sometimes rectally), where they dissolve and deliver the hormone directly to the uterus. They are prescribed most often during fertility treatments, in early pregnancy to reduce miscarriage risk, and to prevent preterm birth in women with a short cervix. What makes the vaginal route unusual is that it gets far more progesterone into the uterine lining than you’d expect from the blood levels it produces, a quirk of anatomy that makes suppositories the preferred delivery method for many reproductive situations.

Why the Vaginal Route Delivers More Than It Seems To

When progesterone is swallowed as a pill, it passes through the liver before reaching the rest of the body. The liver breaks down a large share of it on that first pass, which means you need a high oral dose to get meaningful amounts into the bloodstream, and even then, the drug’s byproducts can cause drowsiness and other side effects. A vaginal suppository sidesteps the liver entirely. The vaginal walls absorb progesterone and shuttle it through local blood vessels and lymphatic channels directly toward the uterus.¹

Researchers call this the “first uterine pass effect.” After vaginal administration, progesterone concentrations in the uterine tissue can be more than ten times higher than what you’d achieve by injecting progesterone into a muscle, even though the injection produces blood levels roughly seven times higher.² One head-to-head study measured endometrial progesterone directly and found that vaginal delivery produced tissue concentrations roughly eight times those seen in women who ovulate naturally and far higher than the best results from intramuscular shots.³ The practical upshot is that a suppository can drench the uterine lining in progesterone while keeping bloodstream levels relatively low, which limits the systemic side effects that come with high circulating hormone levels.⁴

The Main Clinical Uses

The reasons doctors prescribe progesterone suppositories cluster into a few distinct scenarios, each backed by its own body of evidence.

Luteal Phase Support During IVF

After egg retrieval in an IVF cycle, the ovaries often don’t produce enough progesterone on their own to prepare the uterine lining for an embryo. Supplemental progesterone fills that gap. Vaginal suppositories and gels are the most widely used form for this purpose. A trial comparing vaginal, subcutaneous, and intramuscular progesterone for luteal support found that clinical pregnancy rates were not significantly different across the three routes, though the intramuscular group had a higher rate of chemical pregnancies (positive pregnancy test without a developing embryo).⁵ Another trial comparing vaginal suppositories to intramuscular injections directly found no statistically significant difference in pregnancy rates between the two groups.⁶

A randomized trial comparing vaginal suppositories to oral progesterone before embryo transfer found similar live birth rates between the two routes (about 41–44%), despite the oral form producing higher blood levels.⁷ This reinforces the theme: blood levels of progesterone don’t tell the whole story when the vaginal route concentrates the hormone where it matters most.

Preventing Miscarriage in Early Pregnancy

Two large UK-based trials have shaped current practice here. The PRISM trial enrolled over 4,100 women experiencing early pregnancy bleeding and randomized them to vaginal micronized progesterone (400 mg twice daily) or placebo. Overall, the live birth rate was three percentage points higher in the progesterone group, but that difference didn’t quite reach statistical significance.⁸ The finding that changed practice came from a pre-planned subgroup analysis: among women who had vaginal bleeding and a history of three or more prior miscarriages, the live birth rate jumped from about 57% with placebo to about 72% with progesterone.⁹

The companion PROMISE trial, which focused on women with recurrent miscarriage but without requiring current bleeding, found a similar pattern: a modest overall benefit that grew larger as the number of prior losses increased. Based on these findings, many guidelines now recommend vaginal progesterone for women who present with early-pregnancy bleeding and have a history of at least one prior miscarriage. For a first-time pregnancy with bleeding but no history of loss, the evidence is less convincing.

Preventing Preterm Birth

This is the use with arguably the strongest evidence behind it. In women carrying a single baby who are found on ultrasound to have a short cervix (25 mm or less), daily vaginal progesterone has been shown to cut the rate of early preterm delivery roughly in half. A landmark trial published in the New England Journal of Medicine found that spontaneous delivery before 34 weeks occurred in about 19% of the progesterone group versus 34% of the placebo group.¹⁰ A meta-analysis pooling individual patient data found that vaginal progesterone reduced preterm delivery by about 45% in women with a short cervix, and that you’d need to treat roughly 11 women to prevent one case of very early preterm birth.¹¹ The benefit held regardless of whether the woman had previously delivered early.

One important caveat: the evidence supports vaginal progesterone specifically for singleton pregnancies with a short cervix. For twin pregnancies, or for women with a normal cervix length even if they delivered early before, the data are less clear. A 2023 evidence review concluded that vaginal progesterone should only be recommended in singleton pregnancies with a short cervix.¹²

Suppositories, Gels, and Inserts

Not all vaginal progesterone products are the same shape. The term “suppository” usually refers to a bullet-shaped waxy or oil-based formulation (Cyclogest is a common brand), but your doctor might also prescribe a bioadhesive gel (Crinone) or an effervescent vaginal insert (Endometrin). These differ in how quickly they dissolve, how much residue they leave, and how often you need to use them, but they deliver the same hormone to the same place.

An effervescent vaginal insert, for example, dissolves rapidly and was shown to achieve higher endometrial tissue concentrations and faster absorption than intramuscular progesterone in oil.¹³ In a head-to-head trial comparing suppositories to vaginal inserts, pregnancy rates were similar, but the two formats differed in nuisance factors: suppositories were rated as more inconvenient for leaking and interference with sexual activity.¹⁴ Gel formulations tend to leave behind a waxy residue that some women find bothersome. The choice among these formats often comes down to personal preference and what your clinic stocks.

Side Effects You Should Expect

Vaginal progesterone is generally well tolerated compared to injections (no sore injection sites, no risk of abscess) and compared to oral progesterone (far less drowsiness, since less of the hormone and its sedating metabolites reach the brain). But the vaginal route has its own set of annoyances.

Vaginal discharge is the most common complaint, because the suppository base has to melt and go somewhere. Perineal irritation affects roughly one in five users of suppositories.¹⁵ In the same trial, switching to rectal administration of the same suppository dropped perineal irritation dramatically, to about 2%, which is worth knowing if vaginal irritation becomes a problem. Bloating, breast tenderness, and mild cramping can occur with any route of progesterone and reflect the hormone’s systemic effects rather than the delivery method.

The messiness factor matters more than it might seem on paper. Many women use these suppositories two or three times a day for weeks or months. Wearing a panty liner, inserting the suppository before bed so gravity isn’t working against you, and lying down for 15 to 20 minutes after insertion are all standard practical tips that clinics share.

Safety for the Baby

A systematic review of randomized trials looking at first-trimester vaginal progesterone for recurrent miscarriage found no significant increase in preterm birth, neonatal death, or fetal genital abnormalities compared to placebo.¹⁶ The PRISM trial, which was the largest placebo-controlled study of vaginal progesterone in early pregnancy, also reported no short-term safety concerns.¹⁷ This reassurance is important because progesterone is being given during the period of organ formation, and earlier synthetic progestins (chemically different compounds) had raised theoretical concerns decades ago. Micronized progesterone, which is chemically identical to the progesterone your body makes, has a cleaner safety profile than those older synthetics.

When to Start and When to Stop

Timing depends on the clinical scenario. In IVF, progesterone supplementation typically starts the day of or the day after egg retrieval (or before transfer in frozen embryo cycles) and continues into the first trimester. One question patients often have is how long they need to keep using it. A study of women with poor ovarian response who stopped progesterone supplementation at the first positive pregnancy test found no difference in ongoing pregnancy or live birth rates compared to women who continued longer.¹⁸ That said, many clinics err on the side of continuing until 8 to 10 weeks of pregnancy, when the placenta takes over progesterone production. Your clinic’s protocol is the one to follow.

For preterm birth prevention, vaginal progesterone is usually started at 16 to 24 weeks once a short cervix is identified and continued daily until about 36 weeks. For miscarriage prevention, the typical regimen from the PRISM trial was 400 mg twice daily starting as soon as bleeding appeared and continuing until 16 weeks of gestation.

The Rectal Route as a Backup

When vaginal administration isn’t possible, whether because of vaginal bleeding, infection, discomfort, or patient preference, the same suppositories can sometimes be used rectally. One fertility protocol for frozen embryo transfer cycles monitored blood progesterone levels and added rectal suppositories when levels were below target, using a combination of vaginal and rectal dosing to bring hormone levels up.¹⁹ As mentioned earlier, rectal use also produces far less perineal irritation than vaginal use. It’s not the standard first-line approach, but it’s a practical option in specific circumstances.

Vaginal Progesterone in Menopause

Outside of pregnancy, vaginal progesterone suppositories are sometimes prescribed as part of hormone replacement therapy for postmenopausal women. When a woman takes estrogen to manage menopausal symptoms, she also needs progesterone (or a progestin) to protect the uterine lining from overgrowth. Vaginal micronized progesterone can serve this role. A study comparing vaginal micronized progesterone to oral synthetic progestins found that the vaginal route produced a different endometrial pattern: it maintained a secretory-type lining rather than the thin, atrophic lining more commonly seen with oral synthetics.²⁰ Whether that difference matters clinically over the long term is still an open question, but some clinicians prefer natural progesterone for women who experience mood side effects on synthetic progestins.

Mood effects are a real consideration. Progesterone is converted in the body to allopregnanolone, a neurosteroid that acts on the same brain receptors as anti-anxiety drugs. In some women this has a calming effect, but in others it produces irritability or low mood. A study of postmenopausal women taking sequential vaginal progesterone explored the relationship between allopregnanolone levels and mood changes, testing doses of 400 and 800 mg per day.²¹ The response varies between individuals, and there is no reliable way to predict who will feel better or worse on progesterone.

Luteal Phase Defect Outside of IVF

Before IVF dominated fertility treatment, vaginal progesterone suppositories were already being used for women whose ovaries produced too little progesterone after ovulation, a condition called luteal phase defect. One early study identified this problem in about 8% of infertile women and treated them with vaginal suppositories for at least six months. Among those with no other fertility issues, 70% conceived and over half carried to term.²² The diagnosis of luteal phase defect has become somewhat controversial in reproductive medicine since then, with debate over whether it’s a distinct entity or a normal variant, but vaginal progesterone remains one of the standard treatments when the diagnosis is made.

Premenstrual Syndrome and the Limits of Off-Label Use

Progesterone suppositories were once widely recommended for premenstrual syndrome, based on the theory that PMS symptoms reflected a progesterone deficiency in the second half of the menstrual cycle. The evidence turned out to be disappointing. A double-blind, placebo-controlled trial using 200 mg vaginal suppositories twice daily found that the response to progesterone was “at best, marginal and not significantly different from response with placebo.”²³ A smaller trial did report some benefit for anxiety and irritability symptoms specifically, suggesting that progesterone’s neurosteroid metabolites might help a subset of women.²⁴ The overall picture is that vaginal progesterone is not a reliable PMS treatment for most women, and current guidelines generally don’t recommend it for that purpose. The fact that it was once popular speaks to how compelling the “replace the missing hormone” logic can feel, even when trials don’t back it up.

How Progesterone Acts on the Uterine Lining

The reason progesterone matters so much in early pregnancy is that it drives a transformation of the uterine lining called decidualization. After ovulation, progesterone signals the endometrial cells to stop proliferating and start differentiating into the spongy, blood-vessel-rich tissue that an embryo needs to implant and grow. Research using gene-expression profiling has shown that progesterone acts through two receptor types in the uterus, each controlling overlapping but distinct sets of genes critical for establishing pregnancy.²⁵ Without adequate progesterone signaling, the lining can’t sustain an implanting embryo, which is the biological rationale behind supplementation in IVF, early pregnancy, and luteal phase defect.

Vaginal suppositories exploit this biology directly. Because the first uterine pass effect delivers a disproportionate amount of the hormone straight to the endometrium, lower systemic doses can achieve the tissue concentrations needed for decidualization. A pharmacokinetic study comparing oral and vaginal progesterone found that the vaginal formulation delivered roughly 18 times the drug exposure (measured by the area under the concentration-time curve) compared to the same dose taken orally.²⁶ That study also noted that genetic variation in liver enzymes affected how quickly oral progesterone was broken down, adding yet another layer of unpredictability to the oral route that the vaginal route largely avoids.